Across TCGA pan-cancer cohorts, TMA16 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TMA16 data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher TMA16 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMA16 expression acts as an unfavorable survival marker.

LUSC, SCLC, and LIHC are the cancer types where TMA16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.112	0.762	<.001	30	view →
SCLC	OS	Median	All	0.082	0.822	<.001	9	view →
LIHC	OS	Median	All	0.164	0.688	.030	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: TMA16 tumor-vs-normal RNA expression · all TMA16 data types